Journals / Annals of Medical Research / 2022 / Cilt: 29 - Sayı: 5

Prostate gland localization with fiducial markers

Pages
487–490
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Treatment margin must be determined carefully, especially in patients who have elevate body mass index and use hormone theraphy, if gold markers can not be used.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Prostate gland inter-intra fraction organ motion cause uncertainties on both target organ definition and risky organ doses.
📊
Key Findings & Data:Materials-methods: This study involved 31 patients with prostate cancer who had placement of gold markers into the prostate gland before radiotheraphy.
💡
Conclusion & Impact:Treatment margin must be determined carefully, especially in patients who have elevate body mass index and use hormone theraphy, if gold markers can not be used.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Prostate gland inter-intra fraction organ motion cause uncertainties on both target organ definition and risky organ doses. The aim of this study is to determine axis shifts between gold markers and pelvic bony structures by using electronic portal images and factors which affects these shifts at prostate cancer patients who had gold marker implantation before radiotheraphy. Materials-methods: This study involved 31 patients with prostate cancer who had placement of gold markers into the prostate gland before radiotheraphy. In the course of treatment, electronic portal images were used for field control with guidance of gold markers every other day. Treatment fields determined by using bony structures and gold markers respectively. Lateral, longitudinal and vertical axis shifts (minimum, mean, maximum) between gold markers and pelvic bony structures were evaluated and the factors which attracted these shifts were examined. Results: We assessed a total of 1683 electronic portal images, and we determined axis shifts between gold markers and bony structures mean laterally minimum 0.3 (0-3)mm, mean 0.4 (0.5-3.2)mm, maximum 3.2 (1-6)mm; longitudinally minumum 0.5 (0- 4) mm, mean 2.4 (0.8-8.4) mm and maximum 6.1 (2-12) mm; vertically minumum 0.5 (0- 2) mm, mean 1.8 (0.4-4) mm and maximum 4.3 (1-7). The relation between maximum lateral axis shift values and using hormone-replacement theraphy; minimum vertical axis shift values and body mass index were statiscally significant (p=0.02, p=0.03 ). Conclusion:We established a statistically significant relation between lateral axis shift maximum values and using hormone-replacement theraphy; minimum vertical axis shift values and body mass index(p=0.02, p=0.03 ). Treatment margin must be determined carefully, especially in patients who have elevate body mass index and use hormone theraphy, if gold markers can not be used.

🔖

Cite This Article

KANYILMAZ, G., ÖNDER, H. (2022). Prostate gland localization with fiducial markers. Annals of Medical Research, Cilt: 29 - Sayı: 5, 487–490. https://ajindex.com/articles/445668

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008
  2. 9 2. Michalski JM, Yan Y, Bruner DW, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial, Int J Radiat Oncol Biol Phys. 2013
  3. Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: longterm results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014
  4. 73 4. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008
  5. 74 5. Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011
  6. Hoogeman MS, Nuyttens JJ, Levendag PC, et al. Time dependence of intrafraction patient motion assessed by repeat stereoscopic imaging. 2008
  7. Gill S, Thomas J, Fox C, et al. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol 2011 Oct 28
  8. 145 8. Rudat V, Nour A, Hammoud M, et al. Image-guided intensitymodulated radiotherapy of prostate cancer: Analysis of interfractional errors and acute toxicity. Strahlenther Onkol. 2016
  9. 17 9. Drozdz S, Schwedas M, Salz H, et al. Prostate cancer treated with image-guided helical TomoTherapy® and image-guided LINAC-IMRT: Correlation between high-dose bladder volume, margin reduction, and genitourinary toxicity. Strahlenther Onkol 2016
  10. 31 10. Welsh JS, Berta C, Borzillary S, et al. Fiducial markers implanted during prostate brachytherapy for guiding conformal external beam radiation therapy. Technol Cancer Res Treat.2004
  11. Dehnad H, Nederveen AJ, van der Heide UA, et al. Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother Oncol. 2003
  12. Shinohara K, Roach M. Technique for implantation of fiducial markers in the prostate. Urology. 2008
  13. Linden RA, Weiner PR, Gomella LG, et al. Techniqu